Essentially, they want to evaluate how effective pevonedistat pus azacitidne is rather than azacitidine alone for people with the conditions listed above. The study needs about 117 people. After enrollment, everyone will be randomly assigned to one of the two different treatment groups for a treatment cycle of 28 days.

This multi-center trial will be conducted worldwide. Patients may qualify for this study if:

18 years of age or older

Patients have intermediate, high, or very high-risk MDS based on the Revised International Prognostic Scoring System (IPSS-R), a standard prognostic tool, or have CMML

Patients have low-blast AML defined as 20% to 30% myeloblasts in the bone marrow (low-blast AML), and ≤30% myeloblasts in the peripheral blood and considered appropriate for azacitidine based therapy

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Keep Up to Date

Learn More

We’ve heard your feedback. Now, by creating a login below, you can customize your homepage to the rare conditions that are most important to you. You can also share your rare story directly through the site, so being part of our community is easier than ever!